Abstract
FMS-like tyrosine kinase 3 internal tandem duplication (FLT3- ITD) mutations are among the most frequent molecular aberrations in patients with acute myeloid leukemia. We retrospectively analyzed 324 patients with acute myeloid leukemia treated with front-line induction chemotherapy between October 2004 and March 2010. Fifty-six patients had FLT3-ITD mutation at diagnosis. Fifty-one (91%) patients with FLT3-ITD achieved complete remission. Thirteen patients had FLT3 analysis at complete remission. None had FLT3-ITD. Twenty-five (49%) patients with FLT3-ITD relapsed. Of these, 13 (52%) had FLT3-ITD at relapse (3 negative and 9 not done). Among the 201 patients without FLT3- ITD at diagnosis who achieved complete remission, 77 (38%) relapsed among whom 8 (10%) patients acquired FLT3- ITD clone. We conclude that FLT3-ITD mutations are unstable at follow up and may occur for the first time at relapse. Therefore, FLT3- ITD is not a reliable marker for minimal residual disease in acute myeloid leukemia.
Original language | English (US) |
---|---|
Pages (from-to) | 1242-1245 |
Number of pages | 4 |
Journal | Haematologica |
Volume | 97 |
Issue number | 8 |
DOIs | |
State | Published - Aug 1 2012 |
Keywords
- Acute myeloid leukemia
- FLT3
- Internal tandem duplication
- Minimal residual disease
- Mutations
ASJC Scopus subject areas
- Hematology